(Q36899705)

17 August 2017

title

Five days of oral topotecan (Hycamtin), a phase I and pharmacological study in adult patients with solid tumours (English)

1 reference

17 August 2017

Gerrits CJ

1

1 reference

17 August 2017

Burris H

2

1 reference

17 August 2017

Schellens JH

3

1 reference

17 August 2017

Planting AS

4

1 reference

17 August 2017

van den Burg ME

5

1 reference

17 August 2017

Rodriguez GI

6

1 reference

17 August 2017

van Beurden V

7

1 reference

17 August 2017

Loos WJ

8

1 reference

17 August 2017

Hudson I

9

1 reference

17 August 2017

Fields S

10

1 reference

17 August 2017

Verweij J

11

1 reference

17 August 2017

von Hoff DD

12

1 reference

17 August 2017

publication date

1 June 1998

1 reference

European Journal of Cancer

17 August 2017

published in

1 reference

17 August 2017

volume

34

1 reference

17 August 2017

issue

7

1 reference

17 August 2017

page(s)

1030-1035

1 reference

Synthesis of water-soluble (aminoalkyl)camptothecin analogs: inhibition of topoisomerase I and antitumor activity

17 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2897%2910173-3

7 January 2021

Evidence for an intermediate with a single-strand break in the reaction catalyzed by the DNA untwisting enzyme

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2897%2910173-3

7 January 2021

Eukaryotic DNA topoisomerase I reaction is topology dependent

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2897%2910173-3

7 January 2021

Regulation of the function of eukaryotic DNA topoisomerase I: topological conditions for inactivity

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2897%2910173-3

7 January 2021

Phase I and pharmacologic study of topotecan: a novel topoisomerase I inhibitor

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2897%2910173-3

7 January 2021

Pharmacokinetics and pharmacodynamics of topotecan administered daily for 5 days every 3 weeks

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2897%2910173-3

7 January 2021

Phase I and pharmacokinetics study of topotecan, a new topoisomerase I inhibitor

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2897%2910173-3

7 January 2021

Phase I Clinical and Pharmacology Study of Topotecan Given Daily for 5 Consecutive Days to Patients With Advanced Solid Tumors, With Attempt at Dose Intensification Using Recombinant Granulocyte Colony-Stimulating Factor

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2897%2910173-3

7 January 2021

Topotecan, an active drug in the second-line treatment of epithelial ovarian cancer: results of a large European phase II study

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2897%2910173-3

7 January 2021

Phase II study of topotecan in metastatic non-small-cell lung cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2897%2910173-3

7 January 2021

Phase II study of topotecan in patients with advanced non-small-cell lung cancer previously untreated with chemotherapy

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2897%2910173-3

7 January 2021

Phase II trial of topotecan in patients with cisplatin-refractory germ cell tumors.

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2897%2910173-3

7 January 2021

Bioavailability and pharmacokinetics of oral topotecan: a new topoisomerase I inhibitor

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2897%2910173-3

7 January 2021

Sensitive high-performance liquid chromatographic fluorescence assay for the quantitation of topotecan (SKF 104864-A) and its lactone ring-opened product (hydroxy acid) in human plasma and urine

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2897%2910173-3

7 January 2021

Understanding the dose-effect relationship: clinical application of pharmacokinetic-pharmacodynamic models

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2897%2910173-3

7 January 2021

Phase I and pharmacologic study of oral topotecan administered twice daily for 21 days to adult patients with solid tumors

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2897%2910173-3

7 January 2021

Clinical studies of irinotecan alone and in combination with cisplatin

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2897%2910173-3

7 January 2021

The current status of camptothecin analogues as antitumor agents

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2897%2910173-3

7 January 2021

Topoisomerase I inhibitors: topotecan and irenotecan

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2897%2910173-3

7 January 2021

10.1016/S0959-8049(97)10173-3

Identifiers

DOI

1 reference

17 August 2017

1 reference